CEACAM5 and cholangiocarcinoma: Scarlett et al. [14] compared the serum profiles of 20 cholangiocarcinoma with those of 20 benign diseases and 25 healthy volunteers and found that the m/z 4,462 peak had superior discriminatory ability compared to the currently used biomarkers, CA19-9 and CEA; the training models developed with panels of peaks from serum protein profiles could distinguish patients with cholangiocarcinoma from those with benign lesions with 65.0% sensitivity and 70.0% specificity, and from sera of healthy volunteers with 75.0% sensitivity and 100% specificity.